These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24477028)

  • 1. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
    Yoshii H; Onuma T; Yamazaki T; Watada H; Matsuhisa M; Matsumoto M; Kitagawa K; Kitakaze M; Yamasaki Y; Kawamori R;
    J Atheroscler Thromb; 2014; 21(6):563-73. PubMed ID: 24477028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
    Charbonnel B; DeFronzo R; Davidson J; Schmitz O; Birkeland K; Pirags V; Scheen A;
    J Clin Endocrinol Metab; 2010 May; 95(5):2163-71. PubMed ID: 20237169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Kaku K; Daida H; Kashiwagi A; Yamashina A; Yamazaki T; Momomura S; Iwase T; Yamasaki Y; Nagatsuka K; Kitagawa K; Kawamori R
    Curr Med Res Opin; 2009 Dec; 25(12):2925-32. PubMed ID: 19835463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Yamasaki Y; Katakami N; Furukado S; Kitagawa K; Nagatsuka K; Kashiwagi A; Daida H; Kawamori R; Kaku K
    J Atheroscler Thromb; 2010 Nov; 17(11):1132-40. PubMed ID: 20686324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
    Suzuki H; Sakamoto M; Hayashi T; Iuchi H; Ohashi K; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
    Cardiovasc Diabetol; 2013 May; 12():71. PubMed ID: 23635096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
    Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
    Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
    de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A
    J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
    Erdmann E; Dormandy J; Wilcox R; Massi-Benedetti M; Charbonnel B
    Vasc Health Risk Manag; 2007; 3(4):355-70. PubMed ID: 17969365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.